Unknown

Dataset Information

0

Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors.


ABSTRACT: Importance:In science and medical research, extreme and dichotomous conclusions may be drawn based on whether the P value falls above or below the threshold. The fragility index (ie, the minimum number of changes from nonevents to events resulting in loss of statistical significance) captures the vulnerability of statistics in trials with binary outcomes. There are a growing number of clinical trials of immune checkpoint inhibitors (ICIs), as well as expanding eligibility for patients to receive them. The robustness of survival outcomes in randomized clinical trials (RCTs) should be evaluated using the fragility index extended to time-to-event data. Objective:To calculate the fragility of survival data in RCTs evaluating ICIs. Design, Setting, and Participants:In this cross-sectional study, data on phase 3 prospective RCTs investigating ICIs included in PubMed from inception until January 1, 2020, were extracted. Two- or three-group studies reporting results for overall survival were eligible for the survival-inferred fragility index (SIFI) calculation, which is the minimum number of reassignments of the best survivors from the interventional group to the control group resulting in loss of significance (defined as P?

SUBMITTER: Bomze D 

PROVIDER: S-EPMC7584930 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors.

Bomze David D   Asher Nethanel N   Hasan Ali Omar O   Flatz Lukas L   Azoulay Daniel D   Markel Gal G   Meirson Tomer T  

JAMA network open 20201001 10


<h4>Importance</h4>In science and medical research, extreme and dichotomous conclusions may be drawn based on whether the P value falls above or below the threshold. The fragility index (ie, the minimum number of changes from nonevents to events resulting in loss of statistical significance) captures the vulnerability of statistics in trials with binary outcomes. There are a growing number of clinical trials of immune checkpoint inhibitors (ICIs), as well as expanding eligibility for patients to  ...[more]

Similar Datasets

| S-EPMC10546826 | biostudies-literature
| S-EPMC4190433 | biostudies-literature
| S-EPMC9745612 | biostudies-literature
| S-EPMC6896022 | biostudies-literature
| S-EPMC8234948 | biostudies-literature
| S-EPMC9847562 | biostudies-literature
| S-EPMC9153072 | biostudies-literature
| S-EPMC9124941 | biostudies-literature
| S-EPMC7697902 | biostudies-literature
| S-EPMC9818635 | biostudies-literature